0000908662-15-000296.txt : 20150819 0000908662-15-000296.hdr.sgml : 20150819 20150819161451 ACCESSION NUMBER: 0000908662-15-000296 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150817 FILED AS OF DATE: 20150819 DATE AS OF CHANGE: 20150819 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DYAX CORP CENTRAL INDEX KEY: 0000907562 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 043053198 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 55 NETWORK DRIVE CITY: BURLINGTON STATE: MA ZIP: 01803-2756 BUSINESS PHONE: 617-250-5769 MAIL ADDRESS: STREET 1: 55 NETWORK DRIVE CITY: BURLINGTON STATE: MA ZIP: 01803-2756 FORMER COMPANY: FORMER CONFORMED NAME: BIOTAGE INC DATE OF NAME CHANGE: 19951117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MIGAUSKY GEORGE V CENTRAL INDEX KEY: 0001134365 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24537 FILM NUMBER: 151064227 MAIL ADDRESS: STREET 1: C/O DYAX CORP. STREET 2: 300 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2015-08-17 0000907562 DYAX CORP DYAX 0001134365 MIGAUSKY GEORGE V C/O DYAX CORP. 55 NETWORK DRIVE BURLINGTON MA 01803-2756 0 1 0 0 EVP & Chief Financial Officer Common Stock 2015-08-17 4 M 0 65000 3.22 A 136350 D Common Stock 2015-08-17 4 M 0 51000 10.20 A 187350 D Common Stock 2015-08-17 4 S 0 64291 22.596 D 123059 D Common Stock 2015-08-17 4 S 0 51709 23.1653 D 71350 D Common Stock 2015-08-17 4 S 0 2306 22.7012 D 21694 I By Trust Common Stock 2015-08-17 4 S 0 694 23.251 D 21000 I By Trust Common Stock 2015-08-17 4 S 0 2436 22.7476 D 18564 I By Trust Common Stock 2015-08-17 4 S 0 564 23.2661 D 18000 I By Trust Common Stock 2015-08-17 4 S 0 2815 22.8207 D 15185 I By Trust Common Stock 2015-08-17 4 S 0 185 23.3781 D 15000 I By Trust Stock Option (right to buy) 3.22 2015-08-17 4 M 0 65000 0 D 2020-02-10 Common Stock 65000 125000 D Stock Option (right to buy) 10.20 2015-08-17 4 M 0 51000 0 D 2024-02-27 Common Stock 51000 93000 D The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.99, inclusive. The reporting person undertakes to provide to Dyax Corp., any security holder of Dyax Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.46, inclusive. The reporting person undertakes to provide to Dyax Corp., any security holder of Dyax Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.15 to $23.10, inclusive. The reporting person undertakes to provide to Dyax Corp., any security holder of Dyax Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4. Shares are held in trusts, of which Mr. Migausky is the trustee, for the benefit of each of Mr. Migausky's children. Mr. Migausky disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.15 to $23.47, inclusive. The reporting person undertakes to provide to Dyax Corp., any security holder of Dyax Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 6. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.16 to $23.15, inclusive. The reporting person undertakes to provide to Dyax Corp., any security holder of Dyax Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 7. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.17 to $23.47, inclusive. The reporting person undertakes to provide to Dyax Corp., any security holder of Dyax Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 8. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.29 to $23.27, inclusive. The reporting person undertakes to provide to Dyax Corp., any security holder of Dyax Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 9. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.30 to $23.47, inclusive. The reporting person undertakes to provide to Dyax Corp., any security holder of Dyax Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 10. The options became fully exercisable on February 10, 2014. The options become exercisable in 48 substantially equal installments at the end of each monthly anniversary of the date of grant, February 27, 2014. /s/ Andrew D. Ashe as attorney-in-fact 2015-08-19